



# Targeted Immunotherapies to Improve the Lives of People with Cancer

---

Nasdaq: ITOS

September 2022

# Forward-Looking Statements



This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of our product candidates; our clinical trials plans and expected timelines; the potential for certain studies to support regulatory submissions; our expected cash runway; and the potential benefits of our collaborations, including with GSK.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the data for our product candidates may not be sufficient to support regulatory approval; iTeos may encounter unanticipated costs or may expend cash more rapidly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos’ control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the impact of the COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in iTeos’ Quarterly Report on Form 10-Q for the six months ended June 30, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company’s cash runway do not indicate when the Company may access the capital markets. Statements regarding the Company’s cash runway do not indicate when the Company may access the capital markets.

Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

# iTeos Has a Unique Opportunity to Lead the Next Wave of Advances in Immuno-Oncology



Growing our pipeline and investigating novel combinations in our mission to improve treatment for multiple cancers

**11**

Clinical studies ongoing/planned including registration-directed trials

**2**

Potential best-in-class therapies with clinical activity in monotherapy and combination



**5**

Strategic collaborations targeted to effectively advance and expand our pipeline

**\$792M\***

Cash balance fully supports execution of data-driven development plans


**100**

R&D scientists with deep knowledge in tumor immunology to design and develop best-in-class therapeutics



\* As of June 30, 2022

# Translating Unique Scientific Capabilities into Differentiated Drug Candidates and Significant Value Creation



# iTeos R&D: Differentiated Approach to Building Pipeline and Sustained Value Creation



## Science-Driven

- 1) iTeos digs deep to understand the TME to identify the best targets
- 2) We design tailored therapeutics to best harness the immune system against cancer



## Growing Capabilities

- 1) Clinical operations to support global, registrational trials
- 2) Translational medicine to maximize potential of programs



## Promising Pipeline

- 1) 3 programs in the clinic over 5-year period
- 2) 2 potential Best in Class drugs in randomized phase 2's
- 3) Strategic partnership to differentiate TIGIT
- 4) Capital-efficient strategy

# Thoughtful IO Drug Development: Maximize Learnings Early for Targeted Late-Stage Development



## Pre-Clinical and Early Clinical: Invest Early to Optimize Development Path

- Conduct initial studies in cancer patients to detect monotherapy benefit
- Invest in translational medicine to identify possible patient/indication selection biomarkers and confirm target engagement and biologic activity
- Explore multiple combinations, with strong preclinical data and reliable historical control, to determine optimal path forward

## Late-Stage Clinical: Incorporate Commercial and Collaborative Potential with Clinical Data

- Aggressively pursue opportunities with high biologic rationale and high unmet need
- Incorporate competitive landscape and commercial potential
- Seek collaborations, where possible, to mitigate cost and expand capabilities

# Differentiated Immuno-Oncology Therapeutic Candidates Rapidly Advancing Through an Expansive Development Strategy





Program	Regimen	Indication	Phase 1	Phase 2	Phase 3
<b>EOS-448</b> FC-Active Anti-TIGIT Antibody	+ dostarlimab	1L NSCLC PDL1 <sup>high</sup>			
		1L HNSCC PDL1 <sup>high/low</sup>			
	+ dostarlimab + CD96	Advanced Malignancies			
	+ dostarlimab + inupadenant	Advanced Malignancies			
	+ inupadenant	Advanced Malignancies			
	monotherapy / + iberdomide	R/R MM			
<b>Inupadenant</b> A <sub>2A</sub> Adenosine Receptor Antagonist	monotherapy	High Biomarker			
	+ pembrolizumab	PD-1 Resistant Melanoma			
	+ chemotherapy	2L Chemo-naive NSCLC			

\* Studies with solid arrows are active. Studies with dashed arrows are planned



EOS-448 /  
GSK4428859A  
FcγR-engaging Anti-TIGIT Antibody

# Expected TIGIT Readouts (2022-2023)



**iTeos Ph2 trials**


- TIG-006 (1L, CPS≥1, HNSCC N=80)
- Lung Platform (1L, PD-L1H, NSCLC, N=300) IA

**Note:** Readouts assumed as 1 month after PCD, except:  
 + Readout timing based on company guidance  
 \* Readout timing based on primary information  
 † Based on internal assessment

<sup>1</sup> SKYSCRAPER-01 guidance is for a readout in H1 2023  
<sup>2</sup> ARC-7 guidance is for a topline readout in H2 2022, presentation in H2 2023


IA – Interim Analysis

# EOS-448 Is Designed to Enhance the Anti-tumor Response Through a Multifaceted Immune Modulatory Mechanism





- 1 Optimized affinity and potency to activate T cell and NK cell killing of tumor cells
- 2 Pro-inflammatory cytokine release and activation of APCs
- 3 Depletion of Tregs and exhausted T cells

## Demonstrated Induction of Effector CD8 T Cells While Depleting Immunosuppressive Tregs



## EOS-448 Depletes TIGIT+ Cells in the Tumor Microenvironment



# Testing Multiple Opportunities for Late-Stage Development

## NSCLC

### HYPOTHESIS:

Leveraging existing data in NSCLC with a differentiated approach

Immune sensitive tumor with strong scientific rationale for TIGIT activity

Triple combinations to engage multiple mechanisms of immunosuppression

Phase 2b

Planned path to registrational trial

## HNSCC

### HYPOTHESIS:

HNSCC opportunity to be among first to market

Immune sensitive tumor with strong scientific rationale for TIGIT activity

Phase 2a

Planned path to registrational trial

## Multiple Myeloma

### HYPOTHESIS:


In collaboration with Fred Hutch, preclinical data showed a key role for TIGIT in multiple myeloma and a stronger anti-tumor response when combined with a CelMod molecule like iberdomide

Phase 2a

Planned path to post transplant patients

# Lung Platform

## Randomized Phase 2 in 1L NSCLC: dostar +/- EOS-448 +/- aCD96 vs. pembro



<b>Study Design</b>	Phase 2, multicenter, randomized, open-label study
<b>Aim</b>	Additive clinical benefit by combining EOS-448 and dostarlimab +/- a-CD96 in 1L NSCLC PDL1 ≥ 50% patients
<b>Biomarker</b>	Assess biomarker status (members of CD226 axis pathway) and outcome in active and control arms in order to define whether biomarker is prognostic, predictive or both. Explore ctDNA as surrogate marker for clinical activity





# Inupadenant

Targeting the Endpoint of the Adenosine Pathway to Maximize Therapeutic Benefit

# Early Clinical Data to Support the Adenosine Pathway

## Ph 2 COAST provides POC for Durva + Oleclumab (CD73) in PACIFIC setting in NSCLC



"We are particularly encouraged by the positive data from the combination therapy of durvalumab and oleclumab. We believe these results not only serve as a proof of concept for oleclumab, but also clinically validate targeting CD73, and probably, broadly the adenosine pathway, for cancer immunotherapy."

- HC WAINWRIGHT


"We believe these (COAST) results are also positive for the combination of checkpoint and adenosine inhibitor mechanisms in NSCLC and other solid tumors"

- SVB LEERINK

# Inupadenant is the First Adenosine Pathway Inhibitor Designed for the Treatment of Cancer


Optimized for Activity at the High Adenosine Concentration Found in Tumors

## Very High Concentrations of Immunosuppressive Adenosine Found in Tumor Microenvironment




Human primary tumor resections; Adenosine quantified by quantitative mass-spec imaging (QMSI)

## Inupadenant is an Insurmountable, Highly Selective $A_{2A}R$ Antagonist



## Potential Predictive Biomarkers Could Help to Optimize our Clinical Strategy



# Testing Multiple Hypotheses and Evaluating External Data to Optimize Development Pathways

Enhance patient selection

**HYPOTHESIS:**

Inupadenant given as monotherapy to patients expressing high levels of biomarkers will have better outcomes (compare to IO-001 and historical controls)

Biomarker-high

Phase 2a ongoing

Combination with immunogenic chemo

**HYPOTHESIS:**

Inupadenant + chemo given post IO (chemo-naïve) can improve outcome compared to chemo alone

2L Chemo-naïve NSCLC

Phase 2b ongoing

Address potential mechanism of resistance

**HYPOTHESIS:**


Inupadenant + aPD-1 given in IO-exposed patients can improve outcome compared to aPD-1 alone (historical control)

PD-1 resistant melanoma

Phase 2a ongoing

# A2A-005

## Randomized Phase 2 in 2L NSCLC (post-IO): chemo vs. chemo + inupadenant



<b>Study Design</b>	Phase 2, multicenter, 2-arm randomized, double-blind, placebo-controlled study
<b>Aim</b>	Additive clinical benefit by combining inupadenant with chemotherapy in 2L NSCLC
<b>Biomarker</b>	Assess biomarker status and outcome in active and control arms in order to define whether biomarker is prognostic, predictive or both

# Combining Expertise in Oncology, a Strong Portfolio, and Dedication to Improve the Lives of People with Cancer

Leverage our deep understanding of targets and our differentiated therapies to select optimal combinations and indications

---

Strong cash position to build our capabilities and reach inflection points

---

Continue to leverage iTeos expertise to progress our internal pipeline and explore external opportunities





# Targeted Immunotherapies to Improve the Lives of People with Cancer

---

Nasdaq: ITOS

September 2022